Stefan D. Anker is Professor of Innovative Clinical Trials (W3) at University Medicine Göttingen (from September 2014). Dr. Anker studied medicine at Charité Berlin and then started his clinical training in Germany completing it in the UK. He obtained his M.D. from Charité Medical School, Berlin, Germany (1993). He went on to earn a Ph.D. (1998) at the National Heart & Lung Institute of Imperial College London. Dr Anker was Professor of Cardiology & Cachexia Research (W2) at Charité Berlin (2002-14).
Dr. Anker has authored more than 600 original papers, reviews, and editorials that are well cited (total citations: >38,000, h-index: 96, papers with ≥ 200 citations: 46; source: Scopus, February 2016). For his work Dr. Anker has won several prizes (including 2 AHA-YIAs), and has obtained a number of fellowships and grants, including 2 NIH grants, 2 EU-FP7 grants & 1 IMI/Horizon2020 grant.
Dr. Anker is Councillor of the Board European Society of Cardiology (ESC, 2014-16). Dr. Anker serves in the board of the Heart Failure Association (HFA) of the ESC since 2006; he was HFA President (2012-14), and currently chairs the HFA committee on regulatory affairs. Dr. Anker is founding Editor-in-Chief of the first open access heart failure journal ESC Heart Failure. Dr. Anker serves on the editorial boards of 5 scientific journals (including European Heart Journal, European Journal of Heart Failure & IJC).
Dr. Anker was and is member of >25 international clinical trial steering committees, chairing or co-chairing several (incl. FAIR-HF & FAIR-HF2, TIM-HF, AUGMENT-HF, RESHAPE-HF2, IMPULSE-HF and BACH). He served in a number of DMC’s (chairing 4) and end-point committees (chairing 4).